Bortezomib plus dexamethasone can improve stem cell collection and overcome the need for additional chemotherapy before autologous transplant in patients with myeloma

References

• Barlogie B, Shaughnessy J, Tricot G, et al Treatment of multiple myeloma. Blood 2004;103:20–32.
   PubMed Web of Science ®Google Scholar
• Gertz MA, Lacy MQ, Dispenzieri A, Hayman SR, Kumar SK. High-dose chemotherapy with autologous hemopoietic stem cell transplantation in patients with multiple myeloma. Expert Rev Anticancer Ther 2006;6:343–360.
   PubMed Web of Science ®Google Scholar
• Harousseau JL. Stem cell transplantation in multiple myeloma (0,1, or 2). Curr Opin Oncol 2005;17:93–98.
   PubMed Web of Science ®Google Scholar
• Kyle RA, Rajkumar SV. Multiple myeloma. New Engl J Med 2004;351:1860–1873.
   PubMed Web of Science ®Google Scholar
• Attal M, Harousseau JL, Stoppa AM, et al A prospective randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. New Engl J Med 1996;335:91–97.
   PubMed Web of Science ®Google Scholar
• Barlogie B, Jagannath S, Vesole DH, et al Superiority of tandem autologous transplantation over standard therapy for previously untreated multiple myeloma. Blood 1997;89:789–793.
   PubMed Web of Science ®Google Scholar
• Child JA, Morgan GJ, Davies FE, et al High-dose chemotherapy with hematopoietic stem cell rescue for multiple myeloma. N Engl J Med 2003;348:1875–1883.
   PubMed Web of Science ®Google Scholar
• Bender JG, To LB, Williams S, Schwartzberg LS. Defining a therapeutic dose of peripheral blood stem cells. J Hematother 1992;1:329–341.
   PubMedGoogle Scholar
• Tricot G, Jagannath S, Vesole D, et al Peripheral blood stem cell transplants for multiple myeloma: identification of favourable variables for rapid engraftment in 225 patients. Blood 1995;85:588–596.
   PubMed Web of Science ®Google Scholar
• Allan DS, Keeney M, Howson-Jan K, et al Number of viable CD34+ cells reinfused predicts engraftment in autologous hematopoietic stem cell transplantation. Bone Marrow Transplant 2002;29:967–972.
   PubMed Web of Science ®Google Scholar
• Morris CL, Siegel E, Barlogie B, et al Mobilization of CD34+ cells in elderly patients (>/=70 years) with multiple myeloma: influence of age, prior therapy, platelet count and mobilization regimen. Br J Hematol 2003;120:413–423.
   PubMed Web of Science ®Google Scholar
• Corso A, Caberlon S, Pagnucco G, et al Blood stem cell collections in multiple myeloma: definition of a scoring system. Bone Marrow Transplant 2000;26:283–286.
   PubMed Web of Science ®Google Scholar
• Alexanian R, Weber D, Giralt S, et al Impact of complete remission with intensive therapy in patients with responsive multiple myeloma. Bone Marrow Transplant 2001;27:1037–1043.
   PubMed Web of Science ®Google Scholar
• Lahuerta JJ, Mateos MV, Martínez-López J, et al Influence of pre- and post-transplantation responses on outcome of patients with multiple myeloma: sequential improvement of response and achievement of complete response are associated with longer survival. J Clin Oncol 2008;26:5775–5782.
   PubMed Web of Science ®Google Scholar
• Nadal E, Giné E, Bladé J, et al High-dose therapy/autologous stem cell transplantation in patients with chemosensitive multiple myeloma: predictors of complete remission. Bone Marrow Transplant 2004;33:61–64.
   PubMed Web of Science ®Google Scholar
• O'Shea D, Giles C, Terpos E, et al Predictive factors for survival in myeloma patients who undergo autologous stem cell transplantation: a single-center experience in 211 patients. Bone Marrow Transplant 2006;37:731–737.
   PubMed Web of Science ®Google Scholar
• Van de Velde HJ, Liu X, Chen G, Cakana A, Deraedt W, Bayssas M. Complete response correlates with long-term survival and progression-free survival in high-dose therapy in multiple myeloma. Haematologica 2007;92:1399–1406.
   PubMed Web of Science ®Google Scholar
• Richardson PG, Sonneveld P, Schuster MW, et al Assessment of Proteasome Inhibition for Extending Remissions (APEX) Investigators. Bortezomib or high-dose dexamethasone for relapsed multiple myeloma. New Engl J Med 2005;352:2487–2498.
   PubMed Web of Science ®Google Scholar
• Richardson PG, Sonneveld P, Schuster M, et al Extended follow-up of a phase 3 trial in relapsed multiple myeloma: final time-to-event results of the APEX trial. Blood 2007;110:3557–3560.
   PubMed Web of Science ®Google Scholar
• Jagannath S, Richardson PG, Barlogie B, et al Bortezomib in combination with dexamethasone for the treatment of patients with relapsed and/or refractory multiple myeloma with less than optimal response to bortezomib alone. Haematologica 2006;91:929–934.
   PubMed Web of Science ®Google Scholar
• Jagannath S, Barlogie B, Berenson JR, et al Updated survival analyses after prolonged follow-up of the phase 2, multicenter CREST study of bortezomib in relapsed or refractory multiple myeloma. Br J Haematol 2008;143:537–540.
   PubMed Web of Science ®Google Scholar
• Jagannath S, Durie BG, Wolf J, et al Bortezomib therapy alone and in combination with dexamethasone for previously untreated symptomatic multiple myeloma. Br J Haematol 2005;129:776–783.
   PubMed Web of Science ®Google Scholar
• Harousseau JL, Attal M, Leleu X, et al Bortezomib plus dexamethasone as induction treatment prior to autologous stem cell transplantation in patients with newly diagnosed multiple myeloma: results of an IFM phase II study. Haematologica 2006;91:1498–1505.
   PubMed Web of Science ®Google Scholar
• Rosiñol L, Oriol A, Mateos MV, et al Phase II PETHEMA trial of alternating bortezomib and dexamethasone as induction regimen before autologous stem-cell transplantation in younger patients with multiple myeloma: efficacy and clinical implications of tumor response kinetics. J Clin Oncol 2007;25:4452–4458.
   PubMed Web of Science ®Google Scholar
• Harousseau JL, Mathiot C, Attal M, et al Valcade/dexamethasone (Vel/D) versus VAD as induction treatment prior to autologous stem cell transplantation (ASCT) in newly diagnosed multiple myeloma (MM): updated results of the IFM 2005/01 Trial. Blood 2007;101(Suppl. 1): (Abstract 450).
   Google Scholar
• Jakubowiak A, Kendall T, Al-Zoubi A, et al Initial treatment with Bortezomib (Velcade®), Doxil®, and dexamethasone (VDD) is superior to thalidomide and dexamethasone (TD) as initial therapy prior to autologous stem cell transplantation (ASCT) for multiple myeloma (MM). Blood 2008;112(Suppl. 1): (Abstract 3713).
   PubMed Web of Science ®Google Scholar
• Oakervee HE, Popat R, Curry N, et al PAD combination therapy (PS-341/bortezomib, adriamycin and dexamethasone) for previously untreated patients with multiple myeloma. Br J Haematol 2005;129:755–762.
   PubMed Web of Science ®Google Scholar
• Popat R, Oakervee HE, Curry N, et al Long-term follow-up of PAD for untreated multiple myeloma. Haematologica 2007;92(Suppl. 2): (Abstract Po-725).
   PubMedGoogle Scholar
• Sonneveld P, Van der Holt B, Schmidt-Wolf IGH, et al First analysis of HOVON-65/GMMG-HD4 randomized phase III trial comparing bortezomib, adriamycine, dexamethasone (PAD) vs. VAD as induction treatment prior to high dose melphalan (HDM) in patients with newly diagnosed multiple myeloma (MM). Haematologica 2009;94(Suppl. 2): (Abstract 0473).
   Google Scholar
• Corso A, Arcaini L, Caberlon S, et al A combination of dexamethasone, cyclophosphamide, etoposide and cisplatin is less toxic and more effective than high-dose cyclophosphamide for peripheral stem cell mobilization in multiple myeloma. Haematologica 2002;87:1041–1045.
   PubMed Web of Science ®Google Scholar
• Corso A, Mangiacavalli S, Nosari A, et al Efficacy, toxicity, and feasibility of a shorter schedule of DCEP regimen for stem cell mobilization in multiple myeloma. Bone Marrow Transplant 2005;36:951–954.
   PubMed Web of Science ®Google Scholar
• Corso A, Barbarano L, Zappasodi P, et al The VAD-DCEP sequence is an effective pre-transplant therapy in untreated multiple myeloma. Haematologica 2004;89:1124–1127.
   PubMed Web of Science ®Google Scholar
• Durie BG, Harousseau JL, Miguel JS, et al International Myeloma Working Group. International uniform response criteria for multiple myeloma. Leukemia 2006;20:1467–1473.
   PubMed Web of Science ®Google Scholar
• Cancer Therapy Evaluation Program, Common Terminology Criteria for Adverse Events, Version 3.0, DCTD, NCI, NIH, DHHS. Available from http://ctep.cancer.gov [Accessed 31 March 2003; published date 9 August 2006].
   Google Scholar
• Alexanian R, Barlogie B, Tucker S. VAD-based regimens as primary treatment for multiple myeloma. Am J Hematol 1990;33:86–89.
   PubMed Web of Science ®Google Scholar
• Anderson H, Scarffe JH, Ranson M, et al VAD chemotherapy as remission induction for multiple myeloma. Br J Cancer 1995;71:326–330.
   PubMed Web of Science ®Google Scholar
• Segeren CM, Sonneveld P, van der Holt B, et al Vincristine, doxorubicin and dexamethasone (VAD) administered as rapid intravenous infusion for first-line treatment in untreated multiple myeloma. Br J Haematol 1999;105:127–130.
   PubMed Web of Science ®Google Scholar
• Rajkumar SV, Blood E, Vesole D, Fonseca R, Greipp PR. Eastern Cooperative Oncology Group Phase III. Clinical trial of thalidomide plus dexamethasone compared with dexamethasone alone in newly diagnosed multiple myeloma: a clinical trial coordinated by the Eastern Cooperative Oncology Group. J Clin Oncol 2006;24:431–436.
   PubMed Web of Science ®Google Scholar
• Cavo M, Zamagni E, Tosi P, et al Superiority of thalidomide and dexamethasone over vincristine-doxorubicin-dexamethasone (VAD) as primary therapy in preparation for autologous transplantation for multiple myeloma. Blood 2005;106:35–39.
   PubMed Web of Science ®Google Scholar
• Cavo M, DiRaimondo F, Zamagni E, et al Short term thalidomide incorporated into double autologous stem cell transplantation improves outcomes in comparison with double auto-transplantation for multiple myeloma. J Clin Oncol 2009;27:5001–5007.
   PubMed Web of Science ®Google Scholar
• Macro M, Divine M, Uzunhan Y, et al Dexamethasone + thalidomide compared to VAD as pre-transplant treatment in newly diagnosed multiple myeloma: a randomized trial. Blood 2006;108(Suppl. 1): (Abstract 22).
   Google Scholar
• Rosiñol L, Cibeira MT, Bladé J, et al Extramedullary multiple myeloma escapes the effect of thalidomide. Haematologica 2004;89:832–836.
   PubMed Web of Science ®Google Scholar
• Bladé J, Perales M, Rosiñol L, et al Thalidomide in multiple myeloma: lack of response of soft-tissue plasmacytomas. Br J Haematol 2001;113:422–424.
   PubMed Web of Science ®Google Scholar
• Lacy MQ, Gertz MA, Dispenzieri A, et al Long-term results of response to therapy, time to progression and survival with lenalidomide plus dexamethasone in newly diagnosed myeloma. Mayo Clin Proc 2007;82:1179–1184.
   PubMed Web of Science ®Google Scholar
• Kumar S, Giralt S, Stadtmauer EA, et al Mobilization in Myeloma revisited: IMWG consensus perspectives on stem cell collection following initial therapy with thalidomide-, lenalidomide-, or bortezomib-containing regimens. Blood 2009;114:1729–1735.
   PubMed Web of Science ®Google Scholar